<DOC>
	<DOCNO>NCT01080664</DOCNO>
	<brief_summary>EMD Serono decide terminate enrollment base review available clinical data low probability complete trial base observed recruitment rate . Subjects already enrol study continue participation study , consistent protocol , study completion .</brief_summary>
	<brief_title>A Phase I , Dose-escalation Study AS703569 Given Orally Subjects With Haematological Malignancies</brief_title>
	<detailed_description>The goal research study investigate first time safety tolerability new drug ( AS703569 ) , call aurora kinase inhibitor , test treat blood cancer patient different blood cancer . The research study also assess body break AS703569 change occur blood oral dos AS703569 . It also look see improvement blood cancer . The use AS703569 study experimental .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Doseescalation part : Primary secondary acute myeloid leukaemia , include subject : first subsequent relapse standard therapy , establish treatment option ; refractory available therapy , e.g . fail achieve complete remission chemotherapy ; Newlydiagnosed elderly subject ( 60 year ) accord WHO classification ( ≥20 blast bone marrow ) , accept eligible chemotherapy ( first line therapy ) Subjects myelodysplastic syndrome ( IPSS Int2 high risk ) resistant intolerant standard treatment candidate allogeneic HSCT . Subjects chronic myeloid leukaemia chronic , accelerated blastphase , resistant intolerant standard treatment candidate allogeneic HSCT . Subjects myeloproliferative disorder effective treatment option . Subjects acute lymphoblastic leukaemia , relapse , resistant intolerant standard treatment effective treatment option . Subjects chronic lymphocytic leukaemia , relapse , resistant intolerant standard treatment effective treatment option . Subjects nonHodgkin lymphoma , relapse , resistant intolerant standard treatment effective treatment option . Cohort expansion part Primary secondary acute myeloid leukaemia eligible chemotherapy ( first line therapy ) , include subject first subsequent relapse standard therapy , establish treatment option available ; refractory available therapy , e.g . fail achieve complete remission chemotherapy ; Newlydiagnosed elderly subject ( 60 year ) accord WHO classification ( ≥ 20 blast bone marrow ) , accept eligible chemotherapy ( first line therapy ) Subjects chronic myeloid leukaemia chronic accelerate phase , resistant intolerant standard treatment , achieve complete haematological response , candidate allogeneic HSCT . Subjects myeloproliferative disorder effective treatment option . Subjects Philadelphia chromosome positive acute leukaemia include acute lymphoblastic leukaemia blast phase chronic myeloid leukaemia , relapse , resistant intolerant standard treatment effective treatment option . Acute promyelocytic leukaemia . Ongoing uncontrolled bacterial , viral , fungal atypical mycobacterial infection . Hyperleukocytosis &gt; 50x10 ( 9 ) /L leukaemic blast . Chemotherapy , immunotherapy , biologic therapy experimental anticancer therapy within 28days prior study Day1 and/or recover toxicity . Extensive radiotherapy involve ≥30 % bone marrow ( e.g . whole pelvis , half spine ) within 6months prior study Day1 . Active CNS disease involvement . Any condition , include laboratory , medical history prestudy assessment finding , opinion Investigator , constitute risk contraindication participation could interfere study objective , conduct evaluation drug take orally . Clinically relevant cardiac abnormality clinically relevant abnormality . Known infection human immunodeficiency virus , active hepatitis B , hepatitis C. Signs symptom suggestive transmissible spongiform encephalopathy . Major surgery within 2weeks prior study Day1 . Haemoglobin &lt; 8g/dL screening ( transfuse ) . Refractory platelet transfusion ( defined increase &lt; 20.109/L platelet 1hour transfusion ) . Coexistent second malignancy history prior malignancy within previous 3years ( exclude basal squamous cell carcinoma skin , situ carcinoma cervix treat curatively ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>AS703569</keyword>
	<keyword>Aurora Kinase Inhibitor</keyword>
	<keyword>Haematological malignancy</keyword>
</DOC>